This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Amylin receptor agonists like cagrilintide and dual-action compounds show strong potential for obesity treatment, especially when combined with GLP-1 receptor agonists, by targeting both homeostatic and reward-driven eating pathways.
Why it matters
GLP-1 drugs alone produce meaningful but limited weight loss. Adding amylin-based drugs could push results further by targeting a different hormone system that controls hunger, stomach emptying, and food reward.
The numbers in context
Not specified in abstract. References pramlintide, cagrilintide, KBP-series DACRAs, ZP8396, and amycretin.
How the study worked
Narrative review of preclinical and clinical evidence on amylin receptor agonists for obesity. Covers molecular pharmacology, clinical development, genetic variants, and combination strategies.
Who was studied
Adults with obesity (focus of reviewed therapies)
What this study cannot tell us
Narrative review without systematic search or meta-analysis. Most amylin-based agents are still investigational. Long-term efficacy and safety data are limited. Disease-modifying effects beyond weight loss remain unproven.
Read the original research
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Vascular pharmacology, 162, 107563
Citation
Rejili, Mokhtar; Hussain, Md Sadique; Khan, Yumna; Haouala, Faouzi; Ganesan, Subbulakshmi; Sahoo, Samir; Pal, Amrita; Arora, Vimal. (2025). Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.. Vascular pharmacology, 162, 107563. https://doi.org/10.1016/j.vph.2025.107563